Abstract 279P
Background
Oral cavity cancer with the masticator space involvement is considered as very advanced localised disease and staged as T4b in AJCC 8th edition, along with the involvement carotid artery, base of skull or prevertebral fascia. NCCN treatment guidelines consider this as inoperable disease and advocate non-surgical options or palliative treatment. This study intends to compare the different treatment modalities in T4b oral cavity cancer and their impact on survival.
Methods
This is a retrospective study of 150 patients with T4b oral cavity cancer, from 2013 to 2015 and follow up data till 31st July 2019 were collected. All patients had biopsy-proven SCC and CT evidence of masticator space involvement.
Results
Total of 150 patients were included. 102 patients had received curative treatment and 48 patients had received palliative treatment. 30% in the curative group and 42% in the palliative group were supra notch disease. In the curative group 84% were treated with surgery and adjuvant treatment, and the remaining had received RT with or without chemotherapy. 90% patients in the surgically treated group had attained margin negative resection. 4-year OS in the curatively treated group was 58.9% and in the palliative group was 12%. 2-year OS was 69% and 31% respectively, (p=0.001). The survival of supra notch disease was not different from infra notch disease either in the curative group (61% v/s 57%, p=0.452) or in the palliative group (10% v/s 14%, p=0.13). The surgically treated patients in the curative arm had significant survival advantage over the patients who had received only RT with or without chemotherapy, (63.5% v/s 34%, p=0.001).
Conclusions
Curatively treated oral cavity cancer with masticator space involvement has good survival outcome. Clinicopathological spectrum of supra notch disease is not different from infra notch disease, and their prognosis is similar to infra notch disease, if margin-negative resection is attained. Radical intent treatment, preferably surgery should be offered to all patients with masticator space involvement, if negative margin is anticipated from preoperative imaging.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Director, RCC, Trivandrum.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session